Kenvue Poised for Growth After Takeover News, Tylenol Controversy
Kimberly-Clark’s acquisition of Kenvue will create a new consumer products giant.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
Usually, after a takeover the investment opportunity is over, but that’s not the case after Kimberly-Clark’s (KMB) acquisition of Kenvue (KVUE) .
After years of kicking the tires, KMB, the maker of paper products, finally seized an opportunistic time to take over KVUE, the health-related consumer product maker, for cash and stock.
Wall Street has been troubled by Kenvue’s potential liabilities relating to Tylenol and international talc lawsuits, and KMB shares have been punished for taking on the risk. With both KMB and KVUE trading at depressed prices, KVUE offers significant upside from closing the 10% deal discount, a 5% dividend yield and the post-close synergies when the two companies combine.
There should be no allusions about Wall Street’s distaste for Kenvue, but therein lies the opportunity. The stock has been shunned since it was spun off from Johnson and Johnson (JNJ) in 2023 due to failing to live up to earnings and growth expectations, persistent product liability and management flux. Concern about Kenvue’s legal morass caused a 14% decline in KMB on the deal announcement. Again, as Wall Street frets and discounts a poor outcome, investors can buy on the cheap as the selloff discounts a bad outcome.
The merger creates a multi-year opportunity for patient value investors. When Kimberly-Clark’s consumer products diversify with Kenvue’s more health-related products, like Band-Aids, Aveeno and Listerine, a $32 billion revenue behemoth with a stellar lineup of consumer products will be formed. The valuation of a mid- to high-teens P/E pre-synergies leaves plenty of room for things to go right and also a sufficient margin of safety if things go wrong, as Wall Street already discounts.
The plan for over $2 billion in deal synergies and a 5% dividend yield, compared to 2.9% for Procter & Gamble (PG) and 2.65% and Colgate-Palmolive (CL) , ought to keep value-investors tuned in as the deal progresses. Since KVUE recently reaffirmed its EPS for the remainder of the fiscal year, concerns should be allayed about lost momentum in its sales from potential impaired Tylenol revenue and consumers trading down.
There’s no doubt that it’s been stomach-turning for investors in KVUE to see the president and HHS Secretary blame a rise in autism diagnoses on Tylenol taken during pregnancy, without any additional scientific evidence. Yet, perhaps there’s some comfort that, when the case was litigated in front of a judge, Kenvue prevailed due to the lack of evidence for the linkage. KMB’s board also consulted with the world’s foremost scientific, medical, regulatory and legal experts, according to the CEO.
The consumer staples sector has been one of the few sectors down in 2025. KMB is down 20%, with most losses occurring after the deal announcement, KVUE is down 22% even after the deal pop, and PG is down 13% as its P/E has slid from 25 to 21.
For investors, this means investors can pick up shares of KVUE in an already out-of-favor sector, with an extra discount baked into KMB, mostly from potential litigation concerns. Wall Street’s deal skepticism becomes an opportunity for investors as deal risks have been the focus instead of the room to optimize Kenvue’s portfolio in a combined entity.
I expect to own KVUE through the deal closing in the second half of 2026 — potentially gaining 5% in dividends and 10% from closing the deal discount if KMB merely maintains its share price — and holding after the combination when deal synergies kick in and litigation risk potentially alleviates.
At the time of publication, Ginesin was long KVUE.
